A total of 72 patients were randomly divided into a combination group ( pemetrexed + bevacizumab , n = 36 ) and a pemetrexed group ( n = 36 ) and assessed for disease control ( CR+PR+SD ) after 4-cycles of first-line GP chemotherapy ( gemcitabine + cisplatin ) .